| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 46.94% | Piper Sandler | $300 → $280 | Maintains | Overweight |
| 01/06/2023 | 17.55% | Morgan Stanley | $290 → $224 | Maintains | Equal-Weight |
| 12/12/2022 | 23.33% | Wells Fargo | → $235 | Downgrades | Overweight → Equal-Weight |
| 11/08/2022 | 57.44% | Wells Fargo | $255 → $300 | Maintains | Overweight |
| 10/11/2022 | 52.19% | Morgan Stanley | $255 → $290 | Maintains | Equal-Weight |
| 09/06/2022 | -13.41% | Oppenheimer | → $165 | Downgrades | Perform → Underperform |
| 08/29/2022 | 77.38% | Piper Sandler | $278 → $338 | Maintains | Overweight |
| 08/09/2022 | 33.82% | Morgan Stanley | $201 → $255 | Maintains | Equal-Weight |
| 08/09/2022 | 33.82% | Wells Fargo | $176 → $255 | Maintains | Overweight |
| 08/09/2022 | 45.89% | Piper Sandler | $245 → $278 | Maintains | Overweight |
| 07/15/2022 | 5.48% | Morgan Stanley | $180 → $201 | Maintains | Equal-Weight |
| 05/10/2022 | -5.54% | Morgan Stanley | $199 → $180 | Maintains | Equal-Weight |
| 05/10/2022 | -7.64% | Wells Fargo | $235 → $176 | Maintains | Overweight |
| 05/10/2022 | -8.16% | SVB Leerink | $250 → $175 | Maintains | Outperform |
| 04/06/2022 | 33.82% | Wolfe Research | → $255 | Initiates Coverage On | → Outperform |
| 02/18/2022 | 4.43% | Morgan Stanley | $210 → $199 | Maintains | Equal-Weight |
| 02/18/2022 | -0.29% | SVB Leerink | $160 → $190 | Maintains | Outperform |
| 01/07/2022 | 10.21% | Morgan Stanley | $204 → $210 | Maintains | Equal-Weight |
| 12/06/2021 | 23.33% | Wells Fargo | → $235 | Upgrades | Equal-Weight → Overweight |
| 11/09/2021 | 23.33% | Wells Fargo | $200 → $235 | Maintains | Equal-Weight |
| 11/09/2021 | 39.07% | SVB Leerink | $250 → $265 | Maintains | Outperform |
| 08/10/2021 | 4.96% | Morgan Stanley | $152 → $200 | Maintains | Equal-Weight |
| 08/10/2021 | 15.46% | SVB Leerink | $208 → $220 | Maintains | Outperform |
| 07/15/2021 | 9.16% | SVB Leerink | → $208 | Initiates Coverage On | → Outperform |
| 07/12/2021 | 4.96% | B of A Securities | $180 → $200 | Downgrades | Buy → Neutral |
| 06/18/2021 | -0.81% | Wells Fargo | → $189 | Downgrades | Overweight → Equal-Weight |
| 06/07/2021 | -0.81% | Wells Fargo | $161 → $189 | Maintains | Overweight |
| 05/11/2021 | 6.01% | Canaccord Genuity | $149 → $202 | Maintains | Buy |
| 05/11/2021 | -20.23% | Morgan Stanley | $145 → $152 | Maintains | Equal-Weight |
| 05/11/2021 | -15.51% | Wells Fargo | $151 → $161 | Maintains | Overweight |
| 05/11/2021 | -5.54% | B of A Securities | → $180 | Upgrades | Neutral → Buy |
| 04/19/2021 | -23.9% | Morgan Stanley | $130 → $145 | Maintains | Equal-Weight |
| 03/31/2021 | -21.81% | Canaccord Genuity | $147 → $149 | Maintains | Buy |
| 02/22/2021 | -31.78% | Morgan Stanley | $103 → $130 | Maintains | Equal-Weight |
| 02/19/2021 | -31.78% | Morgan Stanley | $103 → $130 | Maintains | Equal-Weight |
| 02/18/2021 | -29.68% | Piper Sandler | $132 → $134 | Maintains | Neutral |
| 02/02/2021 | -31.25% | Canaccord Genuity | $87 → $131 | Maintains | Buy |
| 01/20/2021 | -30.73% | Piper Sandler | $96 → $132 | Downgrades | Overweight → Neutral |
| 12/15/2020 | -45.95% | Morgan Stanley | $89 → $103 | Maintains | Equal-Weight |
| 11/11/2020 | -53.29% | Morgan Stanley | $72 → $89 | Maintains | Equal-Weight |
| 10/19/2020 | -62.21% | Morgan Stanley | $55 → $72 | Maintains | Equal-Weight |
| 10/16/2020 | -52.77% | Wells Fargo | $80 → $90 | Maintains | Overweight |
| 08/12/2020 | -69.56% | Piper Sandler | $54 → $58 | Maintains | Overweight |
| 08/12/2020 | -71.14% | Morgan Stanley | $42 → $55 | Maintains | Equal-Weight |
| 06/11/2020 | — | Oppenheimer | Upgrades | Underperform → Perform | |
| 06/09/2020 | -72.19% | Canaccord Genuity | $46 → $53 | Maintains | Buy |
| 05/13/2020 | -77.96% | Morgan Stanley | $40 → $42 | Maintains | Equal-Weight |
| 05/13/2020 | -75.86% | Wells Fargo | $43 → $46 | Maintains | Overweight |
| 04/01/2020 | -87.93% | Oppenheimer | → $23 | Downgrades | Perform → Underperform |
| 03/27/2020 | -79.01% | Morgan Stanley | $51 → $40 | Maintains | Equal-Weight |
| 12/17/2019 | -75.33% | Morgan Stanley | $35 → $47 | Maintains | Equal-Weight |
| 12/12/2019 | — | Wells Fargo | Upgrades | Equal-Weight → Overweight | |
| 11/08/2019 | -81.63% | Morgan Stanley | $32 → $35 | Maintains | Equal-Weight |
| 10/22/2019 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 10/21/2019 | -79.53% | Piper Sandler | → $39 | Initiates Coverage On | → Overweight |
| 04/01/2019 | -82.68% | Wells Fargo | → $33 | Initiates Coverage On | → Market Perform |
| 04/01/2019 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
What is the target price for ShockWave Medical (SWAV)?
The latest price target for ShockWave Medical (NASDAQ: SWAV) was reported by Piper Sandler on January 26, 2023. The analyst firm set a price target for $280.00 expecting SWAV to rise to within 12 months (a possible 46.94% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ShockWave Medical (SWAV)?
The latest analyst rating for ShockWave Medical (NASDAQ: SWAV) was provided by Piper Sandler, and ShockWave Medical maintained their overweight rating.
When is the next analyst rating going to be posted or updated for ShockWave Medical (SWAV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ShockWave Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ShockWave Medical was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
Is the Analyst Rating ShockWave Medical (SWAV) correct?
While ratings are subjective and will change, the latest ShockWave Medical (SWAV) rating was a maintained with a price target of $300.00 to $280.00. The current price ShockWave Medical (SWAV) is trading at is $190.55, which is out of the analyst's predicted range.